Alan J. Wein, MD, PhD (hon), FACS, presented “OAB – “Tier 2” Management” during the 1st International Functional and Reconstructive Urology Update on August 29, 2024, in Denver, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Wein, Alan J. “OAB – “Tier 2” Management.” August 29, 2024. Accessed Dec 2024. https://grandroundsinurology.com/oab-tier-2-management/
OAB – “Tier 2” Management – Summary
Alan J. Wein, MD, PhD (hon), FACS, explores the pharmacological management of overactive bladder (OAB), focusing on antimuscarinic medications and beta-3 agonists. In this 13-minute presentation, Wein stresses the importance of setting realistic treatment goals for patients, as no current therapy cures OAB but can manage symptoms. He recommends combining behavioral and drug therapy to achieve better outcomes.
Wein discusses antimuscarinic, anticholinergic, and Beta-3 agonist medications in detail. The efficacy of these drugs varies. Overall, while both drug classes offer benefits in managing OAB, the choice of therapy should consider side effects, patient age, and cognitive risks. His presentation concludes with the recommendation that beta-3 agonists may be a safer first-line therapy due to their favorable side-effect profile.
About The 1st International Functional and Reconstructive Urology Update (IFRUU)
The International Functional and Reconstructive Urology Update is a multi-day meeting focused on functional and reconstructive urology (FRU). FRU is a rapidly expanding subspecialty with the vision to improve the lives of all patients with urinary disorders. The IFRUU conference aims to equip practitioners with the tools to manage patients with functional urologic disorders effectively. The inaugural IFRUU conference took place from August 28-30, 2024 in Denver, Colorado.
For further educational activities from this conference, visit our collection page.